Indian biotechnology company Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, Reuters news agency reported on Monday, citing a source with direct knowledge of the matter.
According to the source, who did not want to be named as the information was private, said the product might need a small trial in India before it could be rolled out as a booster or standalone vaccine.
The source also said that Gennova has separately submitted to India's drug regulator phase 2 trial data for its original mRNA vaccine candidate.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer